The first swine flu vaccines could be available to Americans by the first week of October. However, Barbara Loe Fisher, President of the National Vaccine Information Center, has expressed concerns about the vaccination.
With the latest statistics indicating 300 thousand people are infected worldwide, the early distribution of vaccine shots is crucial to curb the spread of the illness.
The vaccine has been linked to syndromes such as Guillain-Barré syndrome, but nothing has been heard about preliminary results of clinical tests. Moreover, the tests include only 2000 people, which is not enough to really understand the reaction profile of this vaccine, acknowledged Loe Fisher.
“What I’m really concerned about is that are they going to count the really bad reactions that may occur in these clinical trials, or after the vaccine is used, as being associated with the vaccine. Many times they write off anything bad that happens after a vaccination as being a coincidence, when they really don’t know if that’s true,” Loe Fisher told RT.